Patient’s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19()()

OBJECTIVES: Self-administered subcutaneous (SC) depot medroxyprogesterone acetate (DMPA) can improve contraception access by eliminating a health center visit for administration. For patients at our New York City health centers who were offered a switch to self-administered DMPA-SC at the onset of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Tiffany Joyce, Urdanigo, Talia K., Shroff, Nandini, Rubin, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015826/
https://www.ncbi.nlm.nih.gov/pubmed/36931548
http://dx.doi.org/10.1016/j.contraception.2023.110008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015826/
https://www.ncbi.nlm.nih.gov/pubmed/36931548
http://dx.doi.org/10.1016/j.contraception.2023.110008

Ejemplares similares